BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer.

ABBV-744 ARV-825 BRD4 c-Myc p53 senescence

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
11 Aug 2023
Historique:
received: 29 06 2023
revised: 03 08 2023
accepted: 07 08 2023
medline: 26 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

Breast cancer is the most commonly occurring malignancy in women and the second most common cause of cancer-related deaths. ER

Identifiants

pubmed: 37627092
pii: cancers15164066
doi: 10.3390/cancers15164066
pmc: PMC10452571
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : R01 CA260819
Pays : United States

Références

Cancer Detect Prev. 2002;26(5):370-5
pubmed: 12518867
Int J Clin Oncol. 2019 Mar;24(3):262-273
pubmed: 30392115
Int J Mol Sci. 2022 Dec 02;23(23):
pubmed: 36499487
Curr Mol Med. 2013 Sep;13(8):1229-40
pubmed: 23865427
Br J Cancer. 2022 Jun;126(10):1363-1365
pubmed: 35304605
Mol Oncol. 2020 Oct;14(10):2504-2519
pubmed: 32652830
J Exp Clin Cancer Res. 2021 May 19;40(1):174
pubmed: 34011395
Cancer Biol Ther. 2014 Aug;15(8):1000-12
pubmed: 24801380
Cells. 2020 Feb 03;9(2):
pubmed: 32028565
Lancet Oncol. 2022 Mar;23(3):382-392
pubmed: 35123662
Int J Cancer. 2011 Apr 15;128(8):1813-21
pubmed: 20549698
Cancer Med. 2013 Dec;2(6):826-35
pubmed: 24403256
Mol Cells. 2019 Dec 31;42(12):821-827
pubmed: 31838837
Breast Cancer Res Treat. 2019 Jul;176(2):429-434
pubmed: 30895534
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
Am J Transl Res. 2019 Sep 15;11(9):5728-5739
pubmed: 31632543
Biochem Pharmacol. 2008 Oct 15;76(8):947-57
pubmed: 18657518
J Natl Cancer Inst. 2015 Mar 30;107(6):djv048
pubmed: 25825511
Nat Genet. 2015 Jan;47(1):8-12
pubmed: 25547603
Breast Care (Basel). 2020 Aug;15(4):347-354
pubmed: 32982644
Oncol Rep. 2018 Mar;39(3):901-911
pubmed: 29399694
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
Clin Cancer Res. 2000 Nov;6(11):4373-80
pubmed: 11106256
Cancers (Basel). 2021 Feb 10;13(4):
pubmed: 33578753
Clin Cancer Res. 1995 Oct;1(10):1203-8
pubmed: 9815913
Life Sci. 2014 Mar 3;97(2):116-22
pubmed: 24361399
Cell Res. 2014 Jul;24(7):809-19
pubmed: 24874954
Cancers (Basel). 2011 Mar 03;3(1):994-1013
pubmed: 24212651
Cancer Res. 2009 Apr 15;69(8):3405-14
pubmed: 19351845
J Hematol Oncol. 2019 Jul 16;12(1):77
pubmed: 31311566
Mol Cancer. 2022 Aug 30;21(1):171
pubmed: 36042494
Br J Cancer. 1995 Nov;72(5):1259-66
pubmed: 7577479
Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18060-5
pubmed: 23077249
Front Oncol. 2021 Oct 18;11:753119
pubmed: 34733788
Cancer Cell. 2020 Apr 13;37(4):496-513
pubmed: 32289273
Breast Cancer Res Treat. 2020 Nov;184(1):23-35
pubmed: 32783178
Front Oncol. 2020 Nov 26;10:574525
pubmed: 33324552
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Front Oncol. 2023 Jan 18;12:966441
pubmed: 36741704
Mol Cancer Ther. 2021 Oct;20(10):1809-1819
pubmed: 34253595
Cancer Cell Int. 2021 Apr 22;21(1):230
pubmed: 33888130
Cancer Res. 2000 Apr 15;60(8):2155-62
pubmed: 10786679
Drugs Context. 2019 Jul 16;8:212579
pubmed: 31391852
Br J Cancer. 2009 Nov 3;101(9):1606-12
pubmed: 19773755
Nature. 2020 Feb;578(7794):306-310
pubmed: 31969702
Mol Cell. 2018 Aug 16;71(4):592-605.e4
pubmed: 30057199
Autophagy. 2014;10(12):2346-61
pubmed: 25629933
Breast Cancer Res Treat. 2019 Apr;174(3):719-729
pubmed: 30632023
Mol Cell. 2013 Mar 7;49(5):843-57
pubmed: 23317504
Trends Mol Med. 2018 Oct;24(10):871-885
pubmed: 30153969
Biomed Rep. 2016 Jan;4(1):102-106
pubmed: 26870344
Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15081-6
pubmed: 20696891
Cell Res. 2014 Aug;24(8):899-900
pubmed: 25001387
Nat Med. 1995 Oct;1(10):1029-34
pubmed: 7489358
Clin Cancer Res. 1996 Sep;2(9):1439-44
pubmed: 9816318
Cancers (Basel). 2022 Sep 01;14(17):
pubmed: 36077830
Target Oncol. 2019 Feb;14(1):1-12
pubmed: 30136059
Clin Breast Cancer. 2005 Apr;6 Suppl 1:S5-8
pubmed: 15865849
Mol Pharmacol. 2022 Mar;101(3):168-180
pubmed: 34907000
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
Front Pharmacol. 2021 Jan 26;11:621093
pubmed: 33574760
Cancer Drug Resist. 2022 Jun 01;5(2):472-486
pubmed: 35800378
Mol Cancer. 2018 Nov 22;17(1):164
pubmed: 30466442

Auteurs

Ahmed M Elshazly (AM)

Departments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.

Melanie M Sinanian (MM)

Departments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.

Victoria Neely (V)

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Philips Institute for Oral Health Research, School of Dentistry, Virginia Commonwealth University, Richmond, VA 23298, USA.

Eesha Chakraborty (E)

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
C. Kenneth and Dianne Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA 23298, USA.

Muruj A Alshehri (MA)

Departments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.

Michael K McGrath (MK)

Department of Cellular Biology and Anatomy, MCG Cancer Center, Augusta University, Augusta, GA 30912, USA.

Hisashi Harada (H)

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Philips Institute for Oral Health Research, School of Dentistry, Virginia Commonwealth University, Richmond, VA 23298, USA.

Patricia V Schoenlein (PV)

Department of Cellular Biology and Anatomy, MCG Cancer Center, Augusta University, Augusta, GA 30912, USA.

David A Gewirtz (DA)

Departments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.

Classifications MeSH